MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Computational Pathology-Based TROP2 Biomarker Predicts Clinical Outcomes for Datopotamab Deruxtecan in Non-Small Cell Lung Cancer: Findings from TROPION-Lung01 Phase III Trial

NextEdge Admin

09 Sep 2024

2 min 23 sec

computational pathology,precision oncology,Daiichi Sankyo

The exploratory analysis of the TROPION-Lung01 Phase III trial revealed that TROP2, quantified using AstraZeneca’s computational pathology platform (quantitative continuous scoring or QCS), can predict clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated with datopotamab deruxtecan (Dato-DXd). This analysis highlighted a significantly greater efficacy of datopotamab deruxtecan in patients with TROP2-QCS biomarker positive tumors compared to docetaxel.

TROP2 is a protein found on and inside NSCLC tumor cells, but previous attempts to link TROP2 expression, assessed via conventional immunohistochemistry (IHC), to patient responses were unsuccessful. The QCS platform, however, provided a more precise measure of TROP2 expression, leading to better identification of patients likely to respond to TROP2-directed therapies like Dato-DXd.

In the TROPION-Lung01 trial, patients whose tumors were classified as TROP2-QCS positive (≥75% of tumor cells exhibiting a normalized membrane ratio below 0.56) showed improved progression-free survival (PFS). Among these patients, datopotamab deruxtecan reduced the risk of disease progression or death by 43% compared to docetaxel (median PFS 6.9 vs. 4.1 months). In the nonsquamous NSCLC subgroup without actionable genomic alterations,and with TROP2-QCS biomarker positive tumors this reduction was even more pronounced at 48%.

No new safety concerns were identified, and rates of severe treatment-related adverse events were comparable between the treatment arms. This analysis emphasizes the value of QCS in patient selection, offering insights into why certain patients respond better to TROP2-directed therapies and advancing the development of precision oncology treatments.